Literature DB >> 27247353

Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.

Eric Polley1, Mark Kunkel1, David Evans1, Thomas Silvers1, Rene Delosh1, Julie Laudeman1, Chad Ogle1, Russell Reinhart1, Michael Selby1, John Connelly1, Erik Harris1, Nicole Fer1, Dmitriy Sonkin1, Gurmeet Kaur1, Anne Monks1, Shakun Malik1, Joel Morris1, Beverly A Teicher1.   

Abstract

BACKGROUND: Small cell lung carcinoma (SCLC) is an aggressive, recalcitrant cancer, often metastatic at diagnosis and unresponsive to chemotherapy upon recurrence, thus it is challenging to treat.
METHODS: Sixty-three human SCLC lines and three NSCLC lines were screened for response to 103 US Food and Drug Administration-approved oncology agents and 423 investigational agents. The investigational agents library was a diverse set of small molecules that included multiple compounds targeting the same molecular entity. The compounds were screened in triplicate at nine concentrations with a 96-hour exposure time using an ATP Lite endpoint. Gene expression was assessed by exon array, and microRNA expression was derived by direct digital detection. Activity across the SCLC lines was associated with molecular characteristics using pair-wise Pearson correlations.
RESULTS: Results are presented for inhibitors of targets: BCL2, PARP1, mTOR, IGF1R, KSP/Eg5, PLK-1, AURK, and FGFR1. A relational map identified compounds with similar patterns of response. Unsupervised microRNA clustering resulted in three distinct SCLC subgroups. Associating drug response with micro-RNA expression indicated that lines most sensitive to etoposide and topotecan expressed high miR-200c-3p and low miR-140-5p and miR-9-5p. The BCL-2/BCL-XL inhibitors produced similar response patterns. Sensitivity to ABT-737 correlated with higher ASCL1 and BCL2. Several classes of compounds targeting nuclear proteins regulating mitosis produced a response pattern distinct from the etoposide response pattern.
CONCLUSIONS: Agents targeting nuclear kinases appear to be effective in SCLC lines. Confirmation of SCLC line findings in xenografts is needed. The drug and compound response, gene expression, and microRNA expression data are publicly available at http://sclccelllines.cancer.gov. © Published by Oxford University Press 2016. This work is written by US Government employees and is in the public domain in the United States.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27247353      PMCID: PMC6279282          DOI: 10.1093/jnci/djw122

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  53 in total

1.  Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

Authors:  Stephen K Tahir; Xiufen Yang; Mark G Anderson; Susan E Morgan-Lappe; Aparna V Sarthy; Jun Chen; Robert B Warner; Shi-Chung Ng; Stephen W Fesik; Steve W Elmore; Saul H Rosenberg; Christin Tse
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

Review 2.  BCL-2 family antagonists for cancer therapy.

Authors:  Guillaume Lessene; Peter E Czabotar; Peter M Colman
Journal:  Nat Rev Drug Discov       Date:  2008-12       Impact factor: 84.694

3.  A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.

Authors:  Kyle Holen; Robert DiPaola; Glenn Liu; Antoinette R Tan; George Wilding; Karl Hsu; Nancy Agrawal; Cong Chen; Lingling Xue; Elizabeth Rosenberg; Mark Stein
Journal:  Invest New Drugs       Date:  2011-03-22       Impact factor: 3.850

Review 4.  The emerging role of microRNAs in drug responses.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Curr Opin Mol Ther       Date:  2010-12

5.  MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer.

Authors:  B E Johnson; E Russell; A M Simmons; R Phelps; S M Steinberg; D C Ihde; A F Gazdar
Journal:  J Cell Biochem Suppl       Date:  1996

6.  SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.

Authors:  Sai-Wen Tang; Sven Bilke; Liang Cao; Junko Murai; Fabricio G Sousa; Mihoko Yamade; Vinodh Rajapakse; Sudhir Varma; Lee J Helman; Javed Khan; Paul S Meltzer; Yves Pommier
Journal:  Clin Cancer Res       Date:  2015-03-16       Impact factor: 12.531

7.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.

Authors:  Martin Peifer; Lynnette Fernández-Cuesta; Martin L Sos; Julie George; Danila Seidel; Lawryn H Kasper; Dennis Plenker; Frauke Leenders; Ruping Sun; Thomas Zander; Roopika Menon; Mirjam Koker; Ilona Dahmen; Christian Müller; Vincenzo Di Cerbo; Hans-Ulrich Schildhaus; Janine Altmüller; Ingelore Baessmann; Christian Becker; Bram de Wilde; Jo Vandesompele; Diana Böhm; Sascha Ansén; Franziska Gabler; Ines Wilkening; Stefanie Heynck; Johannes M Heuckmann; Xin Lu; Scott L Carter; Kristian Cibulskis; Shantanu Banerji; Gad Getz; Kwon-Sik Park; Daniel Rauh; Christian Grütter; Matthias Fischer; Laura Pasqualucci; Gavin Wright; Zoe Wainer; Prudence Russell; Iver Petersen; Yuan Chen; Erich Stoelben; Corinna Ludwig; Philipp Schnabel; Hans Hoffmann; Thomas Muley; Michael Brockmann; Walburga Engel-Riedel; Lucia A Muscarella; Vito M Fazio; Harry Groen; Wim Timens; Hannie Sietsma; Erik Thunnissen; Egbert Smit; Daniëlle A M Heideman; Peter J F Snijders; Federico Cappuzzo; Claudia Ligorio; Stefania Damiani; John Field; Steinar Solberg; Odd Terje Brustugun; Marius Lund-Iversen; Jörg Sänger; Joachim H Clement; Alex Soltermann; Holger Moch; Walter Weder; Benjamin Solomon; Jean-Charles Soria; Pierre Validire; Benjamin Besse; Elisabeth Brambilla; Christian Brambilla; Sylvie Lantuejoul; Philippe Lorimier; Peter M Schneider; Michael Hallek; William Pao; Matthew Meyerson; Julien Sage; Jay Shendure; Robert Schneider; Reinhard Büttner; Jürgen Wolf; Peter Nürnberg; Sven Perner; Lukas C Heukamp; Paul K Brindle; Stefan Haas; Roman K Thomas
Journal:  Nat Genet       Date:  2012-09-02       Impact factor: 38.330

Review 8.  Hitting the brakes: targeting microtubule motors in cancer.

Authors:  Gayathri Chandrasekaran; Péter Tátrai; Fanni Gergely
Journal:  Br J Cancer       Date:  2015-07-16       Impact factor: 7.640

9.  Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.

Authors:  Yuki Matsumura; Shigeki Umemura; Genichiro Ishii; Koji Tsuta; Shingo Matsumoto; Keiju Aokage; Tomoyuki Hishida; Junji Yoshida; Yuichiro Ohe; Hiroyuki Suzuki; Atsushi Ochiai; Koichi Goto; Kanji Nagai; Katsuya Tsuchihara
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-20       Impact factor: 4.553

10.  NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.

Authors:  Lydia Meder; Katharina König; Luka Ozretić; Anne M Schultheis; Frank Ueckeroth; Carsten P Ade; Kerstin Albus; Diana Boehm; Ursula Rommerscheidt-Fuss; Alexandra Florin; Theresa Buhl; Wolfgang Hartmann; Jürgen Wolf; Sabine Merkelbach-Bruse; Martin Eilers; Sven Perner; Lukas C Heukamp; Reinhard Buettner
Journal:  Int J Cancer       Date:  2015-09-25       Impact factor: 7.396

View more
  54 in total

1.  MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.

Authors:  Gurkan Mollaoglu; Matthew R Guthrie; Stefanie Böhm; Johannes Brägelmann; Ismail Can; Paul M Ballieu; Annika Marx; Julie George; Christine Heinen; Milind D Chalishazar; Haixia Cheng; Abbie S Ireland; Kendall E Denning; Anandaroop Mukhopadhyay; Jeffery M Vahrenkamp; Kristofer C Berrett; Timothy L Mosbruger; Jun Wang; Jessica L Kohan; Mohamed E Salama; Benjamin L Witt; Martin Peifer; Roman K Thomas; Jason Gertz; Jane E Johnson; Adi F Gazdar; Robert J Wechsler-Reya; Martin L Sos; Trudy G Oliver
Journal:  Cancer Cell       Date:  2017-01-12       Impact factor: 31.743

2.  Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.

Authors:  Eric E Gardner; Benjamin H Lok; Valentina E Schneeberger; Patrice Desmeules; Linde A Miles; Paige K Arnold; Andy Ni; Inna Khodos; Elisa de Stanchina; Thuyen Nguyen; Julien Sage; John E Campbell; Scott Ribich; Natasha Rekhtman; Afshin Dowlati; Pierre P Massion; Charles M Rudin; John T Poirier
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

3.  Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer.

Authors:  Chiara Lazzari; Vanesa Gregorc; Alessandra Bulotta; Alessia Dottore; Giuseppe Altavilla; Mariacarmela Santarpia
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 4.  New Approaches to SCLC Therapy: From the Laboratory to the Clinic.

Authors:  John T Poirier; Julie George; Taofeek K Owonikoko; Anton Berns; Elisabeth Brambilla; Lauren A Byers; David Carbone; Huanhuan J Chen; Camilla L Christensen; Caroline Dive; Anna F Farago; Ramaswamy Govindan; Christine Hann; Matthew D Hellmann; Leora Horn; Jane E Johnson; Young S Ju; Sumin Kang; Mark Krasnow; James Lee; Se-Hoon Lee; Jonathan Lehman; Benjamin Lok; Christine Lovly; David MacPherson; David McFadden; John Minna; Matthew Oser; Keunchil Park; Kwon-Sik Park; Yves Pommier; Vito Quaranta; Neal Ready; Julien Sage; Giorgio Scagliotti; Martin L Sos; Kate D Sutherland; William D Travis; Christopher R Vakoc; Sarah J Wait; Ignacio Wistuba; Kwok Kin Wong; Hua Zhang; Jillian Daigneault; Jacinta Wiens; Charles M Rudin; Trudy G Oliver
Journal:  J Thorac Oncol       Date:  2020-02-01       Impact factor: 15.609

Review 5.  Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.

Authors:  Junko Murai; Anish Thomas; Markku Miettinen; Yves Pommier
Journal:  Pharmacol Ther       Date:  2019-05-23       Impact factor: 12.310

6.  Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors.

Authors:  Sai-Wen Tang; Anish Thomas; Junko Murai; Jane B Trepel; Susan E Bates; Vinodh N Rajapakse; Yves Pommier
Journal:  Clin Cancer Res       Date:  2018-02-01       Impact factor: 12.531

7.  The TMEM127 human tumor suppressor is a component of the mTORC1 lysosomal nutrient-sensing complex.

Authors:  Yilun Deng; Yuejuan Qin; Subramanya Srikantan; Anqi Luo; Zi-Ming Cheng; Shahida K Flores; Kris S Vogel; Exing Wang; Patricia L M Dahia
Journal:  Hum Mol Genet       Date:  2018-05-15       Impact factor: 6.150

8.  Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?

Authors:  Alessandro Inno; Anna Stagno; Stefania Gori
Journal:  Transl Lung Cancer Res       Date:  2018-12

9.  Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.

Authors:  Timothy L Lochmann; Konstantinos V Floros; Mitra Naseri; Krista M Powell; Wade Cook; Ryan J March; Giovanna T Stein; Patricia Greninger; Yuki Kato Maves; Laura R Saunders; Scott J Dylla; Carlotta Costa; Sosipatros A Boikos; Joel D Leverson; Andrew J Souers; Geoffrey W Krystal; Hisashi Harada; Cyril H Benes; Anthony C Faber
Journal:  Clin Cancer Res       Date:  2017-11-08       Impact factor: 12.531

10.  CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics.

Authors:  Augustin Luna; Fathi Elloumi; Sudhir Varma; Yanghsin Wang; Vinodh N Rajapakse; Mirit I Aladjem; Jacques Robert; Chris Sander; Yves Pommier; William C Reinhold
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.